Gout Therapeutics Market (By Product Type, Disease Condition and Key Players) is Estimated to be Around 8 billion by 2025: GlaxoSmithKline plc; Merck& Co. Inc.; AstraZeneca plc; Teijin Pharma Ltd.; Novartis AG; Takeda Pharmaceutical Company Ltd.

Industry Trend Analysis
The global gout therapeutics market is estimated to be around 8 billion by 2025. This market has witnessed tremendous growth in last few years due to preface of various regenerative drugs and escalated acceptance of these biologics for treatment. This can be attributed to their capability to generate potent anti-inflammatory action which speeds up treatment time. Furthermore, many other drugs are currently under clinical trials which are likely to be launched in coming years which will play an important role in the market growth. Rising incidence of gout due to changes in lifestyle, growing alcohol consumption, increasing obesity and ingestion of some specific medications will drive the growth of this market. However, binding regulations and patent expiry of leading drugs will slow down the growth of global market.

Product Outlook and Trend Analysis
Non-steroidal anti-inflammatory drugs (NSAIDs) dominates the global market because of superior level of penetration of drug, lower cost, easy availability, and ability to ease pain faster as compared to other available drugs for gout attacks. Urate lowering agents sector is expected to grow at most prominent rate during forecast period. Increasing adoption and innovation of new drugs is likely to enhance market growth. Colchicines occupies significant share in global market, due to their ability to slow down severe inflammatory response by blocking actions of neutrophils responsible for gout attacks. In 2009, FDA approved use of Colchicines for treating gout related fevers.

Get Sample Copy of This Report@ https://www.qurateresearch.com/report/sample/HnM/QBI-CMR-HnM-55049

Regional Outlook and Trend Analysis
In 2016, the global market was dominated by North America, which can be attributed to various factors such as presence of local primary players, extensive use of gout therapies, and easily availability. U.S. dominated the regional market in 2016, followed by Canada. It is likely to sustain its leading position in the global market during the forecast period, owing to expected launch of new drugs and urate-lowering drugs. In Europe, France and Germany hold highest share for gout disease treatment drugs. Asia-Pacific is projected to witness highest growth rate due to rising incidence of gout disease, increased investments in research for the development of new and alternate therapies. Furthermore, increasing consumption of alcohol and cigarettes, changing life style, and increase in obesity rates is likely to improve growth of gout therapeutics market.

Competitive Insights
Numerous multinational as well as local players dominate the global market. Major players comprise GlaxoSmithKline plc; Merck& Co. Inc.; AstraZeneca plc; Teijin Pharma Ltd.; Novartis AG; Takeda Pharmaceutical Company Ltd.; Savient Pharmaceuticals; and Regeneron Pharmaceuticals. Development of new and innovative products, collaborations and strategic acquisitions are some of the strategies acquired by market players to have competitive advantage over their rivals.

Market Opportunities
Major players in market are shifting their focus towards more serious gout cases in order to meet unmet medical needs of drugs for effective treatments. NSAIDs and Colchicines are expected to attract large investment due to their increasing adoption and success rate in treating acute as well as chronic gout disease. Many players have collaborated for research and development to develop more efficient drug for the treatment of gout diseases. The market will be dominated by urate lowering agents that has ability to prevent gout disease by blocking genes responsible for gout disease. With FDA approval of Zurampic (in 2015) to reduce uric acid level in blood and other new drugs in clinical trials will bring in huge opportunities for key players in the market.

Enquiry about Report@ https://www.qurateresearch.com/report/enquiry/HnM/QBI-CMR-HnM-55049

Gout therapeutic market is segmented as follows –
By Product Type:
Colchicines
Corticosteroids
NSAIDs
Urate-lowering Agents

By Disease Condition:
Acute Gout
Chronic Gout

By Region:
• North America
o U.S
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Rest of Asia-Pacific
• Rest of the World
o Brazil
o South Africa
o Saudi Arabia
o Turkey
o United Arab Emirates
o Others

Buy This Report@ https://www.qurateresearch.com/report/buy/HnM/QBI-CMR-HnM-55049/

Some of the key questions answered by the report are:
• What was the market size in 2016 and forecast from 2017 to 2025?
• What will be the industry market growth from 2017 to 2025?
• What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
• What are the major segments leading the market growth and why?
• Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

About Us:
Qurate Business Intelligence delivers unique market research solutions to its customers and help them to get equipped with refined information and market insights derived from reports. We are committed to providing best business services and easy processes to get the same. Qurate Business Intelligence considers themselves as strategic partners of their customers and always shows the keen level of interest to deliver quality.

Runwal Platinum,
Ramnagar Colony, Bavdhan,
Pune, Maharashtra, India-411021
https://www.qurateresearch.com/
IN +919881074592
info@qurateresearch.com

This release was published on openPR.